🔗 Share this article Social Media Influencers Fueling Parallel Market for Unlicensed Slimming Drug An underground economy for unapproved slimming medications is being driven by social media fitness personalities and sellers on messaging platforms, based on new investigations. Investigational Drug Acquiring Popularity Online Retatrutide, which remains in research studies, is being advertised by social media influencers for its supposed weight-reducing properties. Viewers are urged to message these accounts privately for supplier links, while also receiving promotional offers. Active Commerce on Messaging Platforms Separately, a robust trade exists on messaging services, where groups with thousands of members share “before and after” photos, injection guides and claims of next-day British shipping. Vendors market the drug there before redirecting customers to other platforms for transactions. Learning About Retatrutide Retatrutide is an investigational injection developed by US drugmaker Eli Lilly. The drug targets three intestinal hormones – GLP-1, GIP and pancreatic hormone. Early trials suggest it could help individuals reduce up to 25% of their body weight. Referred to as the “triple G”, the drug is being promoted digitally as the next Ozempic. Medical Experts Voice Concerns Nevertheless, physicians and pharmacists have cautions that the distribution of what remains an unlicensed drug in the UK is worrisome and could lead to individuals injecting substances of uncertain source. Several professionals stated the popularity for retatrutide could be linked to the rising price of approved slimming products such as Mounjaro. Regulatory Status and Enforcement Selling retatrutide on social media or Telegram is prohibited in the UK, as it is an unapproved medication that cannot be marketed or supplied for human use under the Human Medicines Regulations 2012. Several content creators try to circumvent the rules by referring to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and supply can still breach medicines, advertising, and consumer regulations, potentially leading to penalties, prosecution or prison. Platform Reaction and Material Removal According to the social media company, the service has removed problematic content and prohibited associated keywords and query recommendations. The organization stated it was committed to keeping the service safe and allocating resources in strengthening enforcement strategies. Online Trading Activities Research also found groups with up to 9,000 participants marketing the experimental drug using the platform's built-in discovery tool, which operates like a public directory. Entering “retatrutide” instantly brings up channels with numerous of users, filled with images of slimming results, glowing reviews and step-by-step guides for mixing or administering at residence. Within minutes of joining one group, a vendor posted contact information, where the majority of transactions occur. The vendor provided an instruction manual and promised delivery within 48 hours. When asked whether the substance was authentic, one vendor responded: “You can’t be sure.” Another provided a photo of a supposed testing documentation. None inquired about weight, health issues or past usage. Item Information and Pricing Inside these groups, messages display dark colored parcels with postal service labels, claiming to include new batches. One message read: “It took eight of us to load them this morning.” Buyers can choose between powder vials, mixed at residence with purified liquid, or pre-filled pens usually priced at 160 pounds for 20 milligrams. When questioned how much time a injector should be used, vendors give conflicting answers varying between a several days to “depends on your body”. Platform Oversight and Safety Actions A representative for Telegram said it regularly monitored harmful content on its platform including material that promoted the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”. Healthcare Expert Cautions “People are administering materials they cannot confirm. Although the research behind retatrutide is valid, these online versions may not include what they advertise,” stated Jason Murphy, the director of pharmaceutical services at a pharmacy service. Dr Crystal Wyllie of an online medical service linked the increase in demand to current cost increases for authorized weight-loss drugs such as Mounjaro. “With costs increasing, patients are turning to social media. But counterfeit treatments are highly dangerous. You can’t be certain what’s contained or whether the conditions they were produced in was sterile,” she said. Her team has previously seen individuals injured by self-injection from unverified suppliers. “We understand the frustration, but buying from messaging apps or WhatsApp is gambling with your health,” said Wyllie. “These materials could be impure or improperly measured.” Producer Position A representative from the pharmaceutical company said the substance was in third stage clinical trials and had not been evaluated or authorized by any government authority anywhere in the world. “Therefore at this time no one can sell [it] for human use,” they explained, noting that any item “falsely representing itself as a Lilly investigational product not yet approved … may expose patients to possibly significant health risks”.